Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-333 (Dasabuvir) in Treatment-Naïve Genotype 1 Chronic Hepatitis C
NCT00851890Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2009
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of dasabuvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Mar 2009; status: completed.
02
Drugs
dasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00851890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00851890.